SKYE · Skye Bioscience, Inc. · Investor Relations
$1.74
+0.06 (+3.57%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$7.39M
Shares
4.43M
Volume · Oct 5
29.68K
Avg daily vol (29 sessions)
82.67K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-14 | Definitive Transaction Agreement Between Skye Bioscience and Redx Pharma | Event |
| 2026-05-26 | 2026 Annual Meeting of Stockholders | Shareholder meeting |
| 2026-04-16 | GLP-1-Based Therapeutics Summit | Event |
| 2026-03-10 | 2025 Q4 Financial Results & Update Conference Call | Earnings call |
| 2026-01-28 | Keystone Obesity Conference | Conference |
Source: https://ir.skyebioscience.com/